CRVS
Price
$3.24
Change
+$0.01 (+0.31%)
Updated
Apr 17 closing price
Capitalization
220.76M
13 days until earnings call
VRDN
Price
$13.13
Change
+$0.48 (+3.79%)
Updated
Apr 17 closing price
Capitalization
1.07B
19 days until earnings call
Ad is loading...

CRVS vs VRDN

Header iconCRVS vs VRDN Comparison
Open Charts CRVS vs VRDNBanner chart's image
Corvus Pharmaceuticals
Price$3.24
Change+$0.01 (+0.31%)
Volume$775.45K
Capitalization220.76M
Viridian Therapeutics
Price$13.13
Change+$0.48 (+3.79%)
Volume$803.1K
Capitalization1.07B
CRVS vs VRDN Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. VRDN commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and VRDN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (CRVS: $3.24 vs. VRDN: $13.13)
Brand notoriety: CRVS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 107% vs. VRDN: 82%
Market capitalization -- CRVS: $220.76M vs. VRDN: $1.07B
CRVS [@Biotechnology] is valued at $220.76M. VRDN’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, CRVS is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 5 bullish, 3 bearish.
  • VRDN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both CRVS and VRDN are a good buy in the short-term.

Price Growth

CRVS (@Biotechnology) experienced а +12.89% price change this week, while VRDN (@Biotechnology) price change was +15.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.07B) has a higher market cap than CRVS($221M). VRDN YTD gains are higher at: -31.508 vs. CRVS (-39.439). CRVS has higher annual earnings (EBITDA): -25M vs. VRDN (-266.36M). VRDN has more cash in the bank: 718M vs. CRVS (41.7M). CRVS has less debt than VRDN: CRVS (354K) vs VRDN (21.1M). VRDN has higher revenues than CRVS: VRDN (302K) vs CRVS (0).
CRVSVRDNCRVS / VRDN
Capitalization221M1.07B21%
EBITDA-25M-266.36M9%
Gain YTD-39.439-31.508125%
P/E RatioN/AN/A-
Revenue0302K-
Total Cash41.7M718M6%
Total Debt354K21.1M2%
FUNDAMENTALS RATINGS
CRVS vs VRDN: Fundamental Ratings
CRVS
VRDN
OUTLOOK RATING
1..100
1053
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
8272
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
6487
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRVS's Valuation (71) in the Pharmaceuticals Major industry is in the same range as VRDN (92) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as CRVS (82) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRVS’s over the last 12 months.

VRDN's SMR Rating (94) in the Biotechnology industry is in the same range as CRVS (97) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as VRDN (87) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

CRVS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as VRDN (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVRDN
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IARFX16.21N/A
N/A
Invesco Real Estate R6
VMNVX31.62N/A
N/A
Vanguard Global Minimum Volatility Admr
HGXTX14.56N/A
N/A
Hartford Global Impact R5
FSOSX14.24N/A
N/A
Fidelity Series Overseas
BTEUX10.97N/A
N/A
Baron Technology R6

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+0.31%
SYRE - CRVS
37%
Loosely correlated
+2.01%
VRDN - CRVS
36%
Loosely correlated
+3.79%
CRSP - CRVS
34%
Loosely correlated
-0.03%
FULC - CRVS
34%
Loosely correlated
+7.52%
ACRV - CRVS
34%
Loosely correlated
-2.16%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+3.79%
DNLI - VRDN
50%
Loosely correlated
+1.51%
AURA - VRDN
47%
Loosely correlated
-0.74%
TERN - VRDN
47%
Loosely correlated
+7.14%
CCCC - VRDN
45%
Loosely correlated
+13.64%
RGNX - VRDN
45%
Loosely correlated
-3.57%
More